Company Update: Allergan Inc (NYSE:AGN) – Allergan Reaches Out To Family Caregivers Of People With Alzheimer’s Disease With New PSA, Website

[PR Newswire] – DUBLIN, June 14, 2016 /PRNewswire/ — Allergan plc (AGN), a leading global pharmaceutical company, today announced its support of two new caregiver initiatives, a public service announcement (PSA) and a caregiver resource website. Allergan partnered with the Alzheimer’s Foundation of America (AFA) and Kim Campbell—wife of country music legend, Glen Campbell, who is battling Alzheimer’s disease—on a PSA to educate caregivers and family members about the signs and symptoms of moderate stage Alzheimer’s disease and where to turn for support. “As the Campbell family understands firsthand, it is critical that families of people with Alzheimer’s disease know where to turn for help and support,” said Charles J. Fuschillo, Jr., AFA’s president and chief executive officer. Read more on this. Allergan plc (AGN) , with a current value of $95.28B, started trading this morning at $241.65. Today’s price range has been between $240.81 and $244.94 per share with a trailing 52-week range being $195.50 to $340.34. AGN shares are currently priced at 17.09x this year’s forecasted earnings, which makes them relatively expensive compared to the industry’s -0.02x earnings multiple for the same period. And for income investors, the company pays shareholders $0.20 per share annually in dividends, yielding 0.10%. According to a consensus of 14 analysts, the earnings estimate of $3.38 per share would be $1.03 worse than the year-ago quarter and a $0.07 sequential decrease. Investors should also note that the full-year EPS estimate of $14.25 is a $0.82 improvement when compared to the previous year’s annual results. The quarterly earnings estimate is predicated on a consensus revenue forecast of $4.11 Billion. If reported, that would be a 28.27% decrease over the year-ago quarter. In terms of ratings, Guggenheim Initiated AGN at Neutral (Apr 18, 2016). Previously, Piper Jaffray downgraded AGN from Overweight to Neutral. When considering if the stock is under or overvalued, the average price target is $292.63, which is 21.10% above where the stock opened this morning. See more in (NYSE:AGN) Similar Articles: Company Update: Allergan Inc (NYSE:AGN) – Allergan Breaks Ground on $200 Million Waco Facility Expansion Company Update: Allergan Inc (NYSE:AGN) – Allergan, Pfizer call off $US160B deal Company Update: Allergan Inc (NYSE:AGN) – Allergan Presents Data at the 2016 American Academy of Dermatology (AAD) Annual Meeting in Washington D.C.